Monday, 5 October 2015

ECTRIMS 2015 What will Rock your Boat

This week we have ECTRIMS 2015 from Barcelona and it promises to be interesting.

Here is the Programme have a Browse and tell us what to look at 

Is it the New anti-CD20 data the anti-CD-19 data the the anti-CD25 data or CD blahdy blah data or the new repair data.

Let us know

Programme ectrims2015 from BartsMSBlog

This week we will be broadcasting a 'MS Question Time' Google Hangout from the ECTRIMS conference. MS Researchers will start the discussion with new information that has been presented either in platform presentations or in the poster sessions. There won't be a quicker way to get the info!



How to get involved in the Question Time Hangouts:
You can either watch the Question Time Hangout on the Barts MS Blog google+ channel, on our You Tube channel or sign up and join the discussion. As this is a Hangout On Air, lots of people can watch the discussion but only 10 people at a time can join and ask questions. So again, if you would like to be invited and notified when the discussion starts, email us your details: bartsmsblog@gmail.com Otherwise, if you have a question, just tweet us. 

The hangout will be at 15.45 (Barcelona Time) on Friday the 9th October for one hour.

Remember if you are in the hangout with a camera on you, you will be seen and so will whats in the background so think about this and avoid people who don't want to be seen being in camera

37 comments:

  1. The elephant in the room is the results of the Charcot Project. Will anything be announced at ECTRIMS 2015? Team G keeps highlighting Anti-CD20 - I wonder if this is to distract the readers from the results of the Charcot Project? I hope ECTRIMS 2015 has no coverage of EAE research which has put MS research back a generation. The focus should now be on B cells and repair - not more bearded geeks cutting up mice and injecting them with real ale. I hope the late-breaking news has a session where Prof G hands the two mice doctors their P45 and announces that EAE is dead. That would rock my boat. No doubt Team G will be sending out a huge contingent to Barcelona - lots of tapas and Spanish wine and then the usual post of "oh it's been such hard work". My friend in Barcelona will be patrolling the beach for singes of two middle age Brits (Welsh windbag and tight Yorkshire man) in their mankinis with a copy of EAE Monthly under their arms. Prof G will no doubt be staying at the Barcelona Ritz with a vintage Rolls Royce to chauffeur him to the sessions. Perhaps it will be a good ECTRIMS with lots of good news for MSer, but I'll wait and see. I suspect it's really a beer-fest for boring neurologist and MS researchers. I suppose it's the nearest they get to a proper social life. Do you want me to feed the mice while you are away on holiday in Spain?

    ReplyDelete
    Replies
    1. I will be attending to the mice whilst my colleagues are working hard at ECTRIMS but thanks for the offer. Your kind thoughts are, as always, much appreciated. Wishing people would lose their jobs really encourages us to go the extra mile ;-)

      Delete
    2. Whoever you are Anon at 9.44am I am embarrassed for you at some of your comments. I am so grateful for this blog and the team.

      Delete
    3. If B-cells are the new fad in MS therapy and T cells are dead, what is being done in the EAE model as far as B-cells are concerned?

      Delete
    4. Thank you all for this blog and your hard work.

      Delete
    5. Thank you Aidan, it's nice to get a bit of praise once in a while ;-)

      Delete
    6. Charcot has an abstract. I will be there and send a picture of the poster.

      Although the aetiology of Multiple Sclerosis remains elusive, it is clear that Epstein Barr Virus (EBV) and possibly other viruses have a role in the pathogenesis of MS. Laboratory evidence suggests that a Human Endogenous Retrovirus (HERV) could have a role as a trigger or even be the cause of MS, but these data suffer from the lack of any interventional therapy that may assist in determining what will happen if HERVs are suppressed. Recent epidemiological evidence indicates that patients with HIV infection have a significantly lower risk of developing MS and that HIV antiretroviral therapies may be coincidentally inhibiting an endogenous retrovirus or retroelements that are implicated in MS. In order to further investigate this possibility, a 6 month Phase 2b pilot clinical trial was designed as a baseline versus treatment study to investigate the role of an HIV integrase inhibitor, raltegravir, in patients with active RRMS as determined by gadolinium-enhanced MRI. The twenty patients who were enrolled had monthly visits for comprehensive assessment that involved a Gd-enhanced MRI, saliva collection for EBV shedding, blood collection for safety monitoring, virology, including HERVs; measurement of immunological and inflammatory markers, and physical, neurological and quality-of-life determination. Patients were monitored monthly for three months as a baseline, followed by three months of treatment with raltegravir 400mg twice a day. All patients completed the six months trial period. This pilot study determined there were no serious adverse events and no withdrawals due to safety issues. The study drug was well tolerated. This is first clinical study conducted with an anti-retroviral therapy in patients with active RRMS. The effect of therapy on the number and rate of development of lesions on Gd-enhanced MRI, markers of HERV activity and other outcome parameters are currently the subjects of final analysis and review.

      Delete
    7. can't wait to speak to prof gold about this

      Delete
    8. congrats team g looks like an interesting abstract. when will you do a post about this?

      Delete
    9. shall i bring a cheque book to donate money to prof gold outside his poster?

      Delete
    10. what time is this being presented?

      Delete
    11. can you please do an interview with prof gold by his poster?

      Delete
    12. nice work. will results be presented?

      Delete
    13. What if the study is a failure? Until we see the results the abstract says nothing.
      Are these being shown?

      Delete
    14. I have not seen the poster, so I am not sure.

      Delete
    15. I do not know why you bother allowing such nasty comments onto the blog; they are written by someone who is clearly having issues of some kind. I understand even less why you bother responding.

      Delete
    16. I spoke to MD2 about his and it is a case of showing you what we have to deal with and as to respond.....it is red to bull...sorry

      Delete
    17. You can we a wet blanket and roll over which we largely do and then every now and then we bite

      Delete
    18. "I do not know why you bother allowing such nasty comments onto the blog.."
      This is merely a mild example (from our resident "comedian") of what we get on a regular basis, so it shows that not everyone is a fan of Team G. We're not perfect, we can take criticism but rattle our cage too often and occasionally we will bite.

      Delete
    19. When mice bite, is there a lot of damage or is it just a superficial injury?

      Delete
    20. Just a little nip but rats are a whole different ball game.

      Delete
    21. MD's, please be sure to remember that notwithstanding the trolls, there are many people that are incredibly grateful for your work, and this very generous blog

      Delete
    22. Just ignore those people writing such nasty comments - im really glad that you people have this wonderful blog. Keep up the good work - i guess many people do not see the work behind a blog. They just think everything on the internet comes from nowhere!

      Delete
    23. Again, many thanks for the positive comments, I suspect the haters are in a small minority.

      Delete
    24. I want to see Prof Gold's poster

      Delete
  2. From a patient perspective, looking at the topic for Wednesday 7 October teaching Course 5, it is terrifying to think that some clinicians might believe "cognition and fatigue are irrelevant for guiding treatment decisions as they are not measurable in an objective and time-saving fashion." Then, lets purpose to make these two chief complaints measurable in an objective and time-saving fashion so as not to burden these neurologists with the oppressive load persons with MS are forced to carry without proper treatment.

    ReplyDelete
    Replies
    1. Yet cognition and fatigue in MS have huge implications for society, as these are the things that keep people out of work and on welfare.

      Delete
    2. Be careful about representing people with MS as being burdens on society. Bankers, many politicians, civil servants who do little more than file their nails, and many other "working people" can be bigger - and very uninspiring - burdens.

      Delete
    3. This comment has been removed by the author.

      Delete
    4. I've worked most of my life. Now I'm only able to work a few hours a week. I'm just learning how to use a walking frame with a seat as I can no longer walk far without sitting down. I now have strangers asking me how to get disability benefits as I must be getting them. That's how society sees me now.

      Delete
    5. Anon: how long have you been having MS and what kind?

      I walked yesterday ca. 600m in normal speed despite my vertigo and ankle pain (non MS related) and I have been having MS for about 8 years now. That is okay with me as long as I can catch the bus and walk normally. Climbing stairs is also good if you don't like to walk or have vertigo - you can move holding on to the barrier.

      I don't work but I don't miss it at all - office job sucked anyway.

      I will try to walk 1 km tomorrow - we have to keep moving no matter what (easier said than done, I know).

      Delete
    6. 38 years and SPMS. I worked full time for 30 years, loved my job, really miss it. I swam three times a week, perfect BMI. never smoked don't drink and healthy diet. Moved from a house due to falling down the stairs head first every day, 3 years after diagnosis.

      Delete
    7. Errr bankers, civil servants and politicians get MS too - I have met them all and I am one of them....

      Delete
  3. One of the topics most interesting at ECTRIMS involves methods to reduce PML risk on natalizumab. Hopefully, we will hear the blog's comments about the success of dose extension, "Extending natalizumab treatment up to eight weeks shown safe and effective...".

    Also, "PML risk stratification during natalizumab therapy using anti-JCV antibody index and L-selectin" will be a very interesting read worthy of blog comment, I hope.


    ReplyDelete
  4. ' real life use of natalizumab ' gets my attention !! is it going to be the real deal docs? no VW stylee data , is that a promise?

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.